A clinical trial examining LL-37, a salivary antimicrobial peptide, was updated to completed status on August 17, 2026. The study, registered as NCT07414030, is titled "Salivary Antimicrobial Peptides and Severe Early Childhood Caries in Turkish Children." No phase was specified for this trial. The registry entry lists the trial status as COMPLETED as of the date noted. This update reflects only a change in the trial's recorded status on ClinicalTrials.gov. No results, outcomes, or findings have been reported alongside this status change. LL-37 remains classified as an unapproved compound used in research settings. Readers should note that a completed status indicates the trial has concluded data collection or study procedures, not that results are available or have been published. Further details about the trial's design, participant population, and methodology can be found in the official registry listing. For additional context on LL-37 as a research compound, readers can consult the compound overview.
LL-37 Study "Salivary Antimicrobial Peptides and Caries" Marked Completed
Source: https://clinicaltrials.gov/study/NCT07414030